Abstract
Non-beta-lactam inhibitor-based methods were evaluated for detecting plasmid-mediated AmpC beta-lactamases in Klebsiella spp., Escherichia coli, and Proteus mirabilis. Using CLSI methodology and disks containing cefotetan alone and in combination with 400 mug of boronic acid, 9 of 10 positive control strains and 54 of 55 AmpC-PCR-positive clinical isolates were detected. Importantly 71% and 40% of these clinical isolates were susceptible by routine testing to ceftriaxone and ceftazidime, respectively. Boronic acid disks also enhanced detection of expanded-spectrum beta-lactamases in AmpC producers.
MeSH terms
-
Bacterial Proteins / analysis*
-
Bacterial Proteins / antagonists & inhibitors
-
Bacterial Proteins / genetics
-
Boronic Acids / pharmacology
-
Enzyme Inhibitors / pharmacology*
-
Escherichia coli / drug effects
-
Escherichia coli / enzymology*
-
Humans
-
Klebsiella / drug effects
-
Klebsiella / enzymology*
-
Microbial Sensitivity Tests
-
Plasmids / physiology*
-
Proteus mirabilis / drug effects
-
Proteus mirabilis / enzymology*
-
beta-Lactamase Inhibitors
-
beta-Lactamases / analysis*
-
beta-Lactamases / genetics
Substances
-
Bacterial Proteins
-
Boronic Acids
-
Enzyme Inhibitors
-
beta-Lactamase Inhibitors
-
AmpC beta-lactamases
-
beta-Lactamases